resveratrol has been researched along with olaparib in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Chatterjee, S; Das, B; Dash, SR; Dhal, AK; Kundu, CN; Paul, S; Sinha, S | 1 |
| Chatterjee, S; Das, B; Das, C; Dash, SR; Kundu, CN; Paul, S; Sinha, S | 1 |
3 other study(ies) available for resveratrol and olaparib
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Combination of talazoparib and olaparib enhanced the curcumin-mediated apoptosis in oral cancer cells by PARP-1 trapping.
Topics: Adenosine Diphosphate; Amino Acids; Animals; Apoptosis; Cell Line, Tumor; Curcumin; DNA; Humans; Mice; Mouth Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Resveratrol; Ribose | 2022 |
Olaparib enhances the Resveratrol-mediated apoptosis in breast cancer cells by inhibiting the homologous recombination repair pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; BRCA1 Protein; Breast Neoplasms; Cell Line, Tumor; DNA; Endonucleases; Humans; Mice; Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Recombinational DNA Repair; Resveratrol | 2022 |